| Dr Andrew O Lewicky, MD | |
|
3982 N Milwaukee Ave, Chicago, IL 60641-2703 | |
| (773) 282-2000 | |
| (773) 282-9428 |
| Full Name | Dr Andrew O Lewicky |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 54 Years |
| Location | 3982 N Milwaukee Ave, Chicago, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407893449 | NPI | - | NPPES |
| 036044340 | Medicaid | IL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 036044340 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Advocate Illinois Masonic Medical Center | Chicago, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ocular Partners Pllc | 7113829532 | 24 |
| Illinois College Of Optometry | 7416851639 | 69 |
News Archive
Imagine a single drug that could prevent human immunodeficiency virus (HIV) infection, treat patients who have already contracted HIV, and even remove all the dormant copies of the virus from those with the more advanced disease. It sounds like science fiction, but Salk scientists have gotten one step closer to creating such a drug by customizing a powerful defense system used by many bacteria and training this scissor-like machinery to recognize the HIV virus.
Advion, Inc., a leading systems and consumables developer for the life sciences industry, announced during the ABRF 2016 Annual Meeting in Fort Lauderdale, Florida the introduction of a proteins and peptides analysis system, 'TIDES EXPRESS.
The U.S. Preventive Services Task Force has found convincing evidence that screening for syphilis infection in asymptomatic, nonpregnant persons at increased risk for infection provides substantial benefit. The report appears in the June 7 issue of JAMA.
A survey of physicians finds that while most support the professional commitment to report other physicians who they feel are incompetent or impaired, such as from alcohol or drug use, when faced with this situation, many did not follow through on making a report, according to a study in the July 14 issue of JAMA.
Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 6 days ago
| Entity Name | Illinois College Of Optometry |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285612390 PECOS PAC ID: 7416851639 Enrollment ID: O20031120000442 |
News Archive
Imagine a single drug that could prevent human immunodeficiency virus (HIV) infection, treat patients who have already contracted HIV, and even remove all the dormant copies of the virus from those with the more advanced disease. It sounds like science fiction, but Salk scientists have gotten one step closer to creating such a drug by customizing a powerful defense system used by many bacteria and training this scissor-like machinery to recognize the HIV virus.
Advion, Inc., a leading systems and consumables developer for the life sciences industry, announced during the ABRF 2016 Annual Meeting in Fort Lauderdale, Florida the introduction of a proteins and peptides analysis system, 'TIDES EXPRESS.
The U.S. Preventive Services Task Force has found convincing evidence that screening for syphilis infection in asymptomatic, nonpregnant persons at increased risk for infection provides substantial benefit. The report appears in the June 7 issue of JAMA.
A survey of physicians finds that while most support the professional commitment to report other physicians who they feel are incompetent or impaired, such as from alcohol or drug use, when faced with this situation, many did not follow through on making a report, according to a study in the July 14 issue of JAMA.
Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 6 days ago
| Entity Name | Ocular Partners Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295792901 PECOS PAC ID: 7113829532 Enrollment ID: O20040124000306 |
News Archive
Imagine a single drug that could prevent human immunodeficiency virus (HIV) infection, treat patients who have already contracted HIV, and even remove all the dormant copies of the virus from those with the more advanced disease. It sounds like science fiction, but Salk scientists have gotten one step closer to creating such a drug by customizing a powerful defense system used by many bacteria and training this scissor-like machinery to recognize the HIV virus.
Advion, Inc., a leading systems and consumables developer for the life sciences industry, announced during the ABRF 2016 Annual Meeting in Fort Lauderdale, Florida the introduction of a proteins and peptides analysis system, 'TIDES EXPRESS.
The U.S. Preventive Services Task Force has found convincing evidence that screening for syphilis infection in asymptomatic, nonpregnant persons at increased risk for infection provides substantial benefit. The report appears in the June 7 issue of JAMA.
A survey of physicians finds that while most support the professional commitment to report other physicians who they feel are incompetent or impaired, such as from alcohol or drug use, when faced with this situation, many did not follow through on making a report, according to a study in the July 14 issue of JAMA.
Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 6 days ago
| Entity Name | Lopez Lewicky & Korey |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780723403 PECOS PAC ID: 0840217279 Enrollment ID: O20051025001000 |
News Archive
Imagine a single drug that could prevent human immunodeficiency virus (HIV) infection, treat patients who have already contracted HIV, and even remove all the dormant copies of the virus from those with the more advanced disease. It sounds like science fiction, but Salk scientists have gotten one step closer to creating such a drug by customizing a powerful defense system used by many bacteria and training this scissor-like machinery to recognize the HIV virus.
Advion, Inc., a leading systems and consumables developer for the life sciences industry, announced during the ABRF 2016 Annual Meeting in Fort Lauderdale, Florida the introduction of a proteins and peptides analysis system, 'TIDES EXPRESS.
The U.S. Preventive Services Task Force has found convincing evidence that screening for syphilis infection in asymptomatic, nonpregnant persons at increased risk for infection provides substantial benefit. The report appears in the June 7 issue of JAMA.
A survey of physicians finds that while most support the professional commitment to report other physicians who they feel are incompetent or impaired, such as from alcohol or drug use, when faced with this situation, many did not follow through on making a report, according to a study in the July 14 issue of JAMA.
Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andrew O Lewicky, MD 3982 N Milwaukee Ave, Chicago, IL 60641-2703 Ph: (773) 282-2000 | Dr Andrew O Lewicky, MD 3982 N Milwaukee Ave, Chicago, IL 60641-2703 Ph: (773) 282-2000 |
News Archive
Imagine a single drug that could prevent human immunodeficiency virus (HIV) infection, treat patients who have already contracted HIV, and even remove all the dormant copies of the virus from those with the more advanced disease. It sounds like science fiction, but Salk scientists have gotten one step closer to creating such a drug by customizing a powerful defense system used by many bacteria and training this scissor-like machinery to recognize the HIV virus.
Advion, Inc., a leading systems and consumables developer for the life sciences industry, announced during the ABRF 2016 Annual Meeting in Fort Lauderdale, Florida the introduction of a proteins and peptides analysis system, 'TIDES EXPRESS.
The U.S. Preventive Services Task Force has found convincing evidence that screening for syphilis infection in asymptomatic, nonpregnant persons at increased risk for infection provides substantial benefit. The report appears in the June 7 issue of JAMA.
A survey of physicians finds that while most support the professional commitment to report other physicians who they feel are incompetent or impaired, such as from alcohol or drug use, when faced with this situation, many did not follow through on making a report, according to a study in the July 14 issue of JAMA.
Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 6 days ago
Paul Owen Phelps, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2001 N Halsted St Ste 200, Chicago, IL 60614 Phone: 312-888-5754 Fax: 833-989-2458 | |
Dr. David Alan Ramirez Jr., MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 225 E Chicago Ave # 70, Chicago, IL 60611 Phone: 312-227-6180 | |
Curtis James Heisel, Ophthalmology Medicare: Medicare Enrolled Practice Location: 251 E Huron St, Chicago, IL 60611 Phone: 312-227-4000 | |
Dr. John B Bello, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 7447 W Talcott Ave, Suite 406, Chicago, IL 60631 Phone: 773-775-9755 Fax: 773-775-4306 | |
Adrienne Berman, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1740 W Taylor St, Chicago, IL 60612 Phone: 866-600-2273 | |
Jhansi Raju, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 3700 W 26th St, Chicago, IL 60623 Phone: 773-542-5203 Fax: 773-542-5841 | |
Catherine Jane Thomas, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 259 E Erie St Ste 1520, Chicago, IL 60611 Phone: 312-695-8150 Fax: 312-503-8152 |